stockrow
Saturday 7 November 2026
Export LENZ’s income statement to Excel — free account
LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- Revenue
- −72.9%
- EPS
- −67.1%
- Free cash flow
- −147.2%
Quarter to September 2026, against a year earlier
3.47
0.46
+15.28%
Follow LENZ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 19 | 12 | — | 14 | 34 | 84 | +64.0% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | 97.81 | 85.35 | +97.8 pt | ||||||
| EBT | — | — | — | 0 | (68) | (71) | (101) | (70) | (50) | (82) | (140) | +201.3% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (427.62) | (1,134.93) | (427.6) pt | ||||||
| Net income | — | 0 | — | 0 | (68) | (71) | (101) | (70) | (50) | (82) | (140) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.39 | n/m | |||||
| Earnings | — | — | — | 0.00 | (209.49) | (17.14) | (12.88) | (35.72) | (2.34) | (2.85) | (4.49) | n/m | ||||||
| Cash flow | — | — | — | 0.00 | (26.72) | (12.79) | (11.22) | (30.82) | (2.79) | (2.40) | (4.06) | n/m | ||||||
| Capex | — | — | — | 0.00 | (4.73) | (1.39) | (0.84) | (0.02) | (0.02) | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | (31.45) | (14.18) | (12.06) | (30.84) | (2.81) | (2.43) | (4.06) | n/m | ||||||
| Book value | — | — | — | 0.00 | (200.39) | 92.93 | 37.79 | (47.33) | 9.59 | 9.87 | 6.11 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 4 | 8 | 2 | 21 | 29 | 31 | n/m | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | 8.82 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 1.62 | 0.57 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | (6.96) | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (2.44) | 0.67 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | (9) | (53) | (88) | (60) | (59) | (69) | (128) | +292.2% | |||||
| Capex | — | — | — | — | (2) | (6) | (7) | 0 | 0 | (1) | 0 | (11.7%) | ||||||
| Free cash flow | — | — | — | 0 | (10) | (59) | (95) | (60) | (60) | (70) | (128) | +293.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (2) | (11) | 370 | 262 | 49 | 202 | 280 | 189 | n/m | |||||
| Net debt | — | — | — | 2 | (20) | (377) | (268) | (66) | (209) | (292) | (197) | n/m | ||||||
| Shareholders’ equity | — | — | — | (2) | (65) | 384 | 296 | (93) | 204 | 284 | 192 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (3,633.33) | (605.88) | (33.33) | (27.92) | (35.67) | (34.84) | (31.52) | (66.72) | +3,601.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (534.02) | (235.28) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 0.32 | 202.21 | (44.41) | (29.71) | (68.74) | (89.37) | (33.63) | (72.69) | (33.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 27 | 69 | 120 | 6 | 42 | 152 | — | +41.3% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
LENZ Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| UNCY Unicycive Therapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $96.3M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDTX Black Diamond Therapeutics, Inc. | $95.4M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $94.6M | — (loss-making) | — (loss-making) | −72.93% (below 0%: shrinking) | n/m | −147.16% (below 0%: shrinking) | 86.58% | (972.75%) | |
| VANI Vivani Medical, Inc. | $93.8M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | −57.23% (below 0%: shrinking) | 100.00% | (162.74%) | Compare |
| NMRA Neumora Therapeutics, Inc. | $91.5M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ICCC ImmuCell Corporation | $90.4M | 117× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| Median of peers | $94.6M | — | — | −71.87% | — | +11.34% | 16.96% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
8.30%
Entities affiliated with RA Capital Management
13.70%
FMR LLC
11.80%
Alpha Wave Ventures II, LP
11.50%
Entities affiliated with Versant Ventures
8.70%
BlackRock, Inc.
5.80%
Entities affiliated with Squarepoint Capital
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement